LEXICON PHARMACEUTICALS, INC. (LXRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150M 300M 450M Q3 '16: 27.7M Q4 '16: 23M Q1 '17: 18.3M Q2 '17: 12.1M Q3 '17: 26.9M Q4 '17: 34M Q1 '18: 25.4M Q2 '18: 13.8M Q3 '18: 7M Q4 '18: 17.1M Q1 '19: 9.2M Q2 '19: 9.7M Q3 '19: 294.4M Q4 '19: 8.7M Q1 '20: 8M Q2 '20: 9.2M Q3 '20: 6.6M Q4 '20: 199K Q1 '21: 27K Q2 '21: 234K Q3 '21: 23K Q4 '21: 14K Q1 '22: 37K Q2 '22: 35K Q3 '22: 39K Q4 '22: 28K Q1 '23: 24K Q2 '23: 317K Q3 '23: 162K Q4 '23: 702K Q1 '24: 1.1M Q2 '24: 1.6M Q3 '24: 1.8M Q4 '24: 26.6M Q1 '25: 1.3M Q2 '25: 28.9M Q3 '25: 14.2M Q4 '25: 5.5M Q1 '26: 21.1M Q2 '26: 692K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 100M 200M 300M Q1 '17: 18.1M Q2 '17: 11.5M Q3 '17: 26.3M Q4 '17: 33.4M Q1 '18: 24.8M Q2 '18: 13M Q3 '18: 6.4M Q4 '18: 16.5M Q1 '19: 8.7M Q2 '19: 8.4M Q3 '19: 293.9M Q4 '19: 8M Q1 '20: 7.4M Q2 '20: 8.4M Q3 '20: 6M Q4 '20: 199K Q1 '21: 27K Q2 '21: 234K Q3 '21: 23K Q4 '21: 14K Q1 '22: 37K Q2 '22: 35K Q3 '22: 39K Q4 '22: 28K Q1 '23: 24K Q2 '23: 309K Q3 '23: 155K Q4 '23: 632K Q1 '24: 1.1M Q2 '24: 1.5M Q3 '24: 1.7M Q4 '24: 26.2M Q1 '25: 1.2M Q2 '25: 28.8M Q3 '25: 14.2M Q4 '25: 5.3M Q1 '26: 21M Q2 '26: 653K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-80M 0 80M 160M 240M Q3 '16: -34.9M Q4 '16: -31.3M Q1 '17: -42.5M Q2 '17: -33.9M Q3 '17: -29.5M Q4 '17: -29M Q1 '18: -37.7M Q2 '18: -30.3M Q3 '18: -22.9M Q4 '18: -12.4M Q1 '19: -17.5M Q2 '19: -18.5M Q3 '19: 224.7M Q4 '19: -47.2M Q1 '20: -62.4M Q2 '20: -64.6M Q3 '20: 86.7M Q4 '20: -7.5M Q1 '21: -20.8M Q2 '21: -18M Q3 '21: -23M Q4 '21: -25.3M Q1 '22: -23.4M Q2 '22: -24M Q3 '22: -23.1M Q4 '22: -30.3M Q1 '23: -31.1M Q2 '23: -44.2M Q3 '23: -49.6M Q4 '23: -46.7M Q1 '24: -45.3M Q2 '24: -55.4M Q3 '24: -63.7M Q4 '24: -32.7M Q1 '25: -25.7M Q2 '25: 3.7M Q3 '25: -12.2M Q4 '25: -14.8M Q1 '26: -996K Q2 '26: -26.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-80M 0 80M 160M 240M Q3 '16: -36M Q4 '16: -32.4M Q1 '17: -34.9M Q2 '17: -35.1M Q3 '17: -30.7M Q4 '17: -26.6M Q1 '18: -41.8M Q2 '18: -34.5M Q3 '18: -27.4M Q4 '18: -16.8M Q1 '19: -21.8M Q2 '19: -23M Q3 '19: 226.1M Q4 '19: -51.1M Q1 '20: -66.6M Q2 '20: -69.1M Q3 '20: 82.6M Q4 '20: -5.5M Q1 '21: -21M Q2 '21: -18.1M Q3 '21: -23.1M Q4 '21: -25.6M Q1 '22: -23.5M Q2 '22: -24.6M Q3 '22: -23.4M Q4 '22: -30.5M Q1 '23: -31.9M Q2 '23: -44.9M Q3 '23: -50.5M Q4 '23: -49.8M Q1 '24: -48.4M Q2 '24: -53.4M Q3 '24: -64.8M Q4 '24: -33.8M Q1 '25: -25.3M Q2 '25: 3.3M Q3 '25: -12.8M Q4 '25: -15.5M Q1 '26: -1M Q2 '26: -31.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 500K 1M 1.5M Q1 '17: 225K Q2 '17: 537K Q3 '17: 599K Q4 '17: 538K Q1 '18: 533K Q2 '18: 838K Q3 '18: 551K Q4 '18: 569K Q1 '19: 553K Q2 '19: 1.3M Q3 '19: 577K Q4 '19: 774K Q1 '20: 568K Q2 '20: 728K Q3 '20: 633K Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 8K Q3 '23: 7K Q4 '23: 70K Q1 '24: 31K Q2 '24: 166K Q3 '24: 71K Q4 '24: 348K Q1 '25: 30K Q2 '25: 33K Q3 '25: 10K Q4 '25: 201K Q1 '26: 108K Q2 '26: 39K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-140M -70M 0 70M 140M 210M Q3 '16: -35.2M Q4 '16: -48.8M Q1 '17: -85.5M Q2 '17: -32.2M Q3 '17: -34M Q4 '17: -33.7M Q1 '18: -46.8M Q2 '18: -52.5M Q3 '18: -22.2M Q4 '18: -27.1M Q1 '19: -25.6M Q2 '19: -26.9M Q3 '19: 190.7M Q4 '19: -24.4M Q1 '20: -22.1M Q2 '20: -46.3M Q3 '20: -40.4M Q4 '20: -34.2M Q1 '21: -25.2M Q2 '21: -21.9M Q3 '21: -17.1M Q4 '21: -22.8M Q1 '22: -23.4M Q2 '22: -24.4M Q3 '22: -19.4M Q4 '22: -21.6M Q1 '23: -31.6M Q2 '23: -38.1M Q3 '23: -41.6M Q4 '23: -50.5M Q1 '24: -55.1M Q2 '24: -48.5M Q3 '24: -53.6M Q4 '24: -21.5M Q1 '25: -43.8M Q2 '25: 17M Q3 '25: -23.8M Q4 '25: -17.2M Q1 '26: -14.7M Q2 '26: -9.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-100M 0 100M 200M 300M Q3 '15: -25.7M Q4 '15: 265.7M Q1 '16: -43.8M Q2 '16: -47.9M Q3 '16: -35.2M Q4 '16: -48.9M Q1 '17: -85.6M Q2 '17: -32.3M Q3 '17: -34M Q4 '17: -33.7M Q1 '18: -46.8M Q2 '18: -52.5M Q3 '18: -22.2M Q4 '18: -27.2M Q1 '19: -25.7M Q2 '19: -26.9M Q3 '19: 190.7M Q4 '19: -24.4M Q1 '20: -22.1M Q2 '20: -46.3M Q3 '20: -40.4M Q4 '20: -34.3M Q1 '21: -25.2M Q2 '21: -22.8M Q3 '21: -17.4M Q4 '21: -22.9M Q1 '22: -23.5M Q2 '22: -24.4M Q3 '22: -19.4M Q4 '22: -22.8M Q1 '23: -31.9M Q2 '23: -38.3M Q3 '23: -41.7M Q4 '23: -50.5M Q1 '24: -55.1M Q2 '24: -48.8M Q3 '24: -53.9M Q4 '24: -22M Q3 '25: -23.8M Q4 '25: -17.2M Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '15: 103.5M Q2 '15: 103.6M Q3 '15: 103.6M Q4 '15: 115.8M Q3 '18: 105.9M Q1 '19: 106.1M Q2 '19: 106.3M Q3 '19: 116.6M Q4 '19: 106.3M Q1 '20: 106.5M Q2 '20: 107.1M Q3 '20: 117.6M Q1 '21: 143.4M Q2 '21: 144.5M Q3 '21: 145.8M Q1 '22: 149.2M Q2 '22: 149.6M Q3 '22: 174.9M Q1 '23: 189M Q2 '23: 204.8M Q3 '23: 244.9M Q1 '24: 245.4M Q2 '24: 310.8M Q3 '24: 361.5M Q1 '25: 362.1M Q2 '25: 363.6M Q3 '25: 363.4M Q1 '26: 400.2M Q2 '26: 437.7M Q1 '15 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q3 '16: -0.30 Q4 '16: -1.37 Q1 '17: -1.36 Q2 '17: -1.32 Q3 '17: -1.26 Q4 '17: -1.20 Q1 '18: -1.27 Q2 '18: -1.27 Q3 '18: -1.24 Q4 '18: -1.15 Q1 '19: -0.96 Q2 '19: -0.85 Q3 '19: 1.36 Q4 '19: 1.04 Q1 '20: 0.62 Q2 '20: 0.19 Q3 '20: -1.05 Q4 '20: -0.60 Q1 '21: -0.12 Q2 '21: 0.40 Q3 '21: -0.47 Q4 '21: -0.61 Q1 '22: -0.62 Q2 '22: -0.65 Q3 '22: -0.62 Q4 '22: -0.62 Q1 '23: -0.63 Q2 '23: -0.69 Q3 '23: -0.77 Q4 '23: -0.80 Q1 '24: -0.83 Q2 '24: -0.78 Q3 '24: -0.75 Q4 '24: -0.64 Q1 '25: -0.51 Q2 '25: -0.33 Q3 '25: -0.19 Q4 '25: -0.14 Q1 '26: -0.07 Q2 '26: -0.15 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.